{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:12:52Z","timestamp":1771481572925,"version":"3.50.1"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2023.1231720","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T04:48:10Z","timestamp":1688359690000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Multiple myeloma: challenges with deciding the optimal sequencing strategy"],"prefix":"10.3389","volume":"14","author":[{"given":"Anushka","family":"Walia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Tuia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41571-020-00448-y","article-title":"Pragmatic trials with prespecified subgroups: What oncologists can learn from COVID-19","volume":"18","author":"Banerjee","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"844779","DOI":"10.3389\/fonc.2022.844779","article-title":"Beyond clinical trials in patients with multiple myeloma: A critical review of real-world results","volume":"12","author":"Bertamini","year":"2022","journal-title":"Front. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41571-022-00665-7","article-title":"Overall survival as a primary end point in multiple myeloma trials","volume":"19","author":"Cliff","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.18568","article-title":"Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis","volume":"200","author":"Etekal","year":"2023","journal-title":"Br. J. Haematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"200363","DOI":"10.1001\/jamanetworkopen.2020.0363","article-title":"Patient experience captured by quality-of-life measurement in oncology clinical trials","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.14694\/EdBook_AM.2013.33.e302","article-title":"Novel approaches to treatment of \u201cdouble-refractory\u201d multiple myeloma","volume":"2013","author":"Lee","year":"2013","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B7","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12885-022-09980-9","article-title":"Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States","volume":"22","author":"Medhekar","year":"2022","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"218084","DOI":"10.1001\/jamanetworkopen.2021.8084","article-title":"Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: A systematic review","volume":"4","author":"Mohyuddin","year":"","journal-title":"JAMA Netw. Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1016\/s2352-3026(21)00024-7","article-title":"Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: A systematic review","volume":"8","author":"Mohyuddin","year":"","journal-title":"Lancet Haematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"100423","DOI":"10.1016\/j.jcpo.2023.100423","article-title":"Is financial toxicity captured in quality of life assessments in oncology randomized clinical trials?","volume":"36","author":"Olivier","year":"2023","journal-title":"J. Cancer Policy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: A clash of philosophies","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","article-title":"Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193)","volume":"21","author":"Sledge","year":"2003","journal-title":"JCO"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1182\/blood-2019-131617","article-title":"Retrospective analysis of the efficacy of triplet therapy, including lenalidomide, in newly diagnosed multiple myeloma patients who obtained responses less than VGPR after Rd therapy","volume":"134","author":"Takezako","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1158\/1078-0432.CCR-12-2935","article-title":"The clinical viewpoint: Definitions, limitations of RECIST, practical considerations of measurement","volume":"19","author":"Villaruz","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1231720\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T04:48:14Z","timestamp":1688359694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1231720\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":14,"alternative-id":["10.3389\/fphar.2023.1231720"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1231720","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"article-number":"1231720"}}